# Retatrutide Research: Mechanism, Phase 2 Trials, and Ongoing Phase 3 Data > Retatrutide research: how the triple agonist at GIP, GLP-1, and glucagon receptors works, what Phase 2 trials found, and what the TRIUMPH Phase 3 program is studying. How the triple agonist works at the receptor level, what the published trials measured, and the open questions still being studied in TRIUMPH. ## The short version Retatrutide is an investigational triple-agonist peptide. It activates three hormonal signaling pathways at once: GLP-1, GIP, and glucagon. Earlier obesity drugs activated one or two of these pathways. Activating all three together — appetite suppression, insulin enhancement, and increased calorie-burning — appears to drive larger weight losses than any single or dual agonist in direct or indirect comparison. The Phase 2 trials (completed and published) showed up to -24.2% body weight at 48 weeks in obesity, and up to -16.94% in type 2 diabetes. The Phase 3 TRIUMPH program is now running. No Phase 3 results have been published. Retatrutide is not approved by any regulator as of 2026. This page covers the mechanism in detail, the structural pharmacology, and the evidence from each completed trial. Internal links: [retatrutide results](/results) for tabulated efficacy figures; [dosing research](/dosage) for trial doses and half-life. ## How does retatrutide work Retatrutide is a single molecule that binds and activates three class-B G-protein-coupled receptors (GPCRs — protein doorways in cell membranes that relay hormonal signals into the cell) simultaneously: **GLP-1R (glucagon-like peptide-1 receptor):** GLP-1 (an incretin hormone released after eating) stimulates glucose-dependent insulin secretion, slows gastric emptying (reducing how fast food leaves the stomach), and suppresses appetite via central signaling in the hypothalamus and brainstem. **GIPR (glucose-dependent insulinotropic polypeptide receptor):** GIP (another post-meal incretin hormone) enhances insulin secretion and influences adipose (fat tissue) metabolism. Combined GIP + GLP-1 activation has been shown to produce larger weight reduction than either pathway alone. **GCGR (glucagon receptor):** Glucagon normally raises blood glucose during fasting. At the GCGR, controlled agonism by retatrutide increases energy expenditure (calorie-burning) and hepatic (liver) lipid metabolism — an additive weight-loss mechanism absent from GLP-1-only compounds. Cryo-EM structural analysis (Li et al., 2024, Cell Discovery) resolved retatrutide's binding at all three receptors at atomic resolution (2.68/3.26/2.84 Å). Relative potency compared to native hormones: approximately 8.9x at GIPR, 0.3x at GCGR, 0.4x at GLP-1R [3]. The design trades off partial potency at glucagon and GLP-1 receptors for very high GIP potency while keeping the glucagon agonism controlled — enough to add thermogenesis without raising blood glucose meaningfully at the doses studied. All three arms signal via cAMP/PKA (cyclic AMP — the cell's internal messenger for these receptor types) downstream. ## What does retatrutide do In clinical terms, published studies show retatrutide does the following across the three-axis mechanism: 1. **Reduces body weight significantly** — mean -24.2% at 12 mg/48 weeks in the Phase 2 obesity trial [1]. 2. **Lowers HbA1c** — mean -2.02% at 12 mg/24 weeks in the Phase 2 type 2 diabetes trial [2]. 3. **Reduces liver fat** — -82.4% relative reduction at 12 mg/24 weeks in the MASLD substudy; 86% of participants reached normal liver fat [5]. 4. **Improves lipid and blood-pressure markers** — dose-dependent improvements observed across the Phase 2 program [7]. Ongoing TRIUMPH Phase 3 arms are studying retatrutide's effects on obstructive sleep apnea, knee osteoarthritis, cardiovascular outcomes, and chronic kidney disease [10]. ## Retatrutide vs tirzepatide Tirzepatide is an approved dual GIP/GLP-1 agonist. Retatrutide adds a third arm — glucagon receptor agonism — to that dual backbone. This distinction is mechanistically important: the glucagon arm adds energy expenditure and hepatic fat mobilization that tirzepatide does not provide. In indirect comparisons from Phase 2 trial data, retatrutide's -24.2% weight loss at 48 weeks compares to tirzepatide's published Phase 3 weight-loss figures of approximately -20-22% at 72 weeks in the highest-dose arms. Direct head-to-head data do not yet exist in published form — Eli Lilly has a Phase 3 trial comparing the two directly, but results are not published as of mid-2026. Critical caveat: different trial populations, different durations, and different titration schedules make indirect comparison unreliable. No claim of superiority is warranted from existing data. The head-to-head trial will be the appropriate comparison. Neither compound should be confused with "GLP-3" — there is no GLP-3 receptor. Retatrutide is a triple agonist at GIP, GLP-1, and glucagon receptors. The term GLP-3 is a misnomer circulating in popular press and search queries; it does not refer to a real receptor class. ## Phase 2 trial summary: key findings **Phase 1b (Urva et al., Lancet 2022):** 72 adults, T2DM, 12 weeks. Half-life confirmed ~6 days. Placebo-adjusted weight: -8.96 kg at the highest dose cohort. Acceptable safety, GI TEAEs in 63%, mostly mild [4]. **Phase 2 obesity (Jastreboff et al., NEJM 2023):** 338 adults, obesity or overweight + comorbidity, 48 weeks. 12 mg: -24.2% body weight vs -2.1% placebo. GI adverse events dose-dependent, mostly mild-moderate. Heart-rate increase, dose-dependent, peaked week 24 [1]. **Phase 2 type 2 diabetes (Rosenstock et al., Lancet 2023):** 281 adults, T2DM, 36 weeks. 12 mg: HbA1c -2.02% vs -0.01% placebo at 24 weeks; body weight -16.94% vs -3.00% placebo at 36 weeks. No severe hypoglycemia, no deaths [2]. **Phase 2 MASLD substudy (Sanyal et al., Nature Medicine 2024):** 98 adults, obesity/overweight + MASLD + no T2DM, 48 weeks. 12 mg at 24 wk: liver fat -82.4% relative; 86% reached normal liver fat (<5% by MRI-PDFF). Effect sustained to 48 wk (-86.0%) [5]. **2025 meta-analysis (3 RCTs, 878 patients):** Pooled weight difference vs placebo: -14.33%. AE rate RR 1.11 (P=0.24, not significant). Authors conclude appropriate safety profile pending long-term data [8]. ## Is retatrutide fda approved No. As of mid-2026, retatrutide is not approved by the FDA or any regulator. It has no approved indication, no labeled dosing, and is not available as a commercial prescription product. It is an investigational drug in Phase 3 clinical trials. Retatrutide availability in the form of gray-market research-labeled material carries the risks described on the [effects and safety page](/effects): unverified identity, purity, and sterility. The FDA issued over 50 warning letters to retatrutide vendors in 2025. When will retatrutide be available as an approved product? The answer depends on TRIUMPH Phase 3 readout timing and FDA review — neither is publicly confirmed as of this writing. --- Trial data on one investigational compound — published, cited, and held by no clinic and no vendor.